Table 1 Baseline clinical characteristics of the patients
Number of patients (N = 32) | Association with advance LTS score P value ± R 2, as applicable | |
|---|---|---|
Age (yrs) | 65 ± 2 | 0.55 |
BMI | 28 ± 1 | 0.35 |
Gender (%male) | 66 % | 0.56 |
Hypertension | 71 % | 0.09 |
Dyslipidemia | 69 % | 0.12 |
Current smoker | 9 % | 0.45* |
Former smoker | 34 % | |
Diabetes | 34 % | 0.0003 |
HbA1C | 0.062 ± 0.01 | 0.002 (R 2 = 0.4) |
Fasting glucose | 6.2 ± 0.7 | 0.18 |
Thyroid or other endocrine disease | 9 % | 0.38 |
Peripheral vascular disease | 25 % | 0.13 |
History of MI | 34 % | 0.01 |
Valvular heart disease | 56 % | 0.09 |
Coronary artery disease | 75 % | 0.09 |
Congestive heart failure | 16 % | 0.28 |
NYHA class | 1.6 ± 0.1 | 0.94 |
LV ejection fraction | 54 ± 2 | 0.02 (R 2 = 0.17) |
CCS class | 1.9 ± 0.1 | 0.74 |
Creatinine (umol/L) | 83 ± 3 | 0.14 |
Medications: | ||
Anti-platelet/Anti-coagulant | 78 % | 0.12 |
Beta-blocker | 56 % | 0.38 |
Statin | 53 % | 0.55 |
Diuretics | 31 % | 0.07 |
ACEI or ARB | 46 % | 0.11 |
Calcium channel blocker | 43 % | 0.64 |
Insulin | 9 % | 0.30 |
Oral hypoglycemics | 31 % | <0.001 |